Lynk Pharmaceuticals Co. Ltd. raised ¥200 million (US$28 million) in a series C1 financing round to accelerate the clinical development of its second-generation and third-generation JAK inhibitors for cancer and autoimmune diseases.
Tuberculosis (TB) is the 13th leading cause of death in the world, and it is rising together with the increased prevalence of drug-resistant TB in many countries. The Bacille Calmette-Guerin (BCG) vaccine is the only available TB vaccine, and it has been given to more people than any other vaccine. While the BCG vaccine has saved tens of millions of lives, it confers suboptimal protection against pulmonary TB as it is limited to providing protection only until early childhood. Significantly, the BCG vaccine is administered intradermally to confer exceptional mucosal immunity as compared to most other vaccines, which are more commonly administered intramuscularly. Novel strategies to improve the duration of TB mucosal immunity are urgently needed.
Autotaxin (ATX) is an enzyme responsible for the production of lysophosphatidic acid (LPA), which plays a role in the pathogenesis of systemic sclerosis (SSc). Researchers from Mitsubishi Tanabe Pharma Corp. and colleagues have reported on the preclinical evaluation of MT-5562, a novel oral ATX inhibitor, as a therapeutic option for SSc.
At the recent American Transplant Congress, researchers from McGill University presented the discovery and preclinical evaluation of a novel retinoic acid receptor-related orphan receptor γt (RORγt) inhibitor, TF-S14, being developed as a potential therapy to delay skin allograft rejection.
Researchers from the Hospital Universitari Vall d’Hebron and colleagues have reported on the development of Hybri, a hybrid recombinant bispecific fusion protein with immunosuppressive activity that consists of the extracellular domain (ECD) of human PD-L2 fused via a linker to the ECD of human CTLA-4, further fused to the Fc domain of human IgG.
Glucocorticoids are very effective immunosuppressive and anti-inflammatory drugs that cause dose-limiting toxicities in brain, liver and bone preventing their use mainly in chronic disorders. Researchers from Immunext Inc. recently reported results from the therapeutic evaluation of the nontoxic glucocorticoid INX-200 with anti-inflammatory efficacy in a once-per-month injection.
Gracell Biotechnologies Inc. is initiating two clinical trials in China in refractory systemic lupus erythematosus for lead candidate GC-012F, a CD19/B-cell maturation antigen dual-targeting CAR T.
The coming months represent a crucial phase in the development of Selection Inc., a U.S.-German firm that is tackling a target in autoimmune disease that has evaded the best efforts of many other drug developers.
With age, senescent cells become detrimental to tissues. Mayo Clinic scientists have observed this phenomenon in the lung alveoli, where senescent macrophages accumulated in aging tissue and in early stages of non-small-cell lung cancer (NSCLC) driven by the Kras oncogene. “We found that the macrophages were present in the earliest stages of the disease. Strategies targeting these cells for elimination or preventing their accumulation would be worthwhile to test in other conditions (assuming we find they occur),” Darren Baker, a Mayo Clinic senescent cell biologist and senior author of the study, told BioWorld.
RSS
